Cargando…

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to vary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terpos, Evangelos, Mikhael, Joseph, Hajek, Roman, Chari, Ajai, Zweegman, Sonja, Lee, Hans C., Mateos, María-Victoria, Larocca, Alessandra, Ramasamy, Karthik, Kaiser, Martin, Cook, Gordon, Weisel, Katja C., Costello, Caitlin L., Elliott, Jennifer, Palumbo, Antonio, Usmani, Saad Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891472/ https://www.ncbi.nlm.nih.gov/pubmed/33602913 http://dx.doi.org/10.1038/s41408-021-00432-4

Ejemplares similares

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
por: Costello, Caitlin, et al.
Publicado: (2019)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Dimopoulos, Meletios A., et al.
Publicado: (2021)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making
por: Gonzalez-McQuire, Sebastian, et al.
Publicado: (2019)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
por: Musto, Pellegrino, et al.
Publicado: (2021)

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
por: Perrot, Aurore, et al.
Publicado: (2021)

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2023)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
por: Theodoropoulos, Nicholas, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
por: Chari, Ajai, et al.
Publicado: (2020)

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
por: Goldschmidt, Hartmut, et al.
Publicado: (2020)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
por: Ramasamy, Karthik, et al.
Publicado: (2023)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
por: Caers, Jo, et al.
Publicado: (2018)

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
por: Yan, Xiaoyu, et al.
Publicado: (2020)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014)

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
por: Cerchione, Claudio, et al.
Publicado: (2022)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
por: Facon, Thierry, et al.
Publicado: (2022)

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
por: Fotiou, Despina, et al.
Publicado: (2020)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?
por: Terpos, Evangelos
Publicado: (2022)

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
por: Weisel, K., et al.
Publicado: (2022)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
por: San-Miguel, Jesus, et al.
Publicado: (2020)

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2018)

BCMA in Multiple Myeloma—A Promising Key to Therapy
por: Kleber, Martina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1kcab31ojsgf111u6l7kk60bjc